Ask Anything
Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
Guideline11 mentionsExpert CommentaryAHA Professional Heart Daily Highlight
JUL 8DiDomenicoCirculation
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Supports deprescribing assessment in CVD polypharmacy across ages; extends prior evidence beyond older adults to the full lifespan.
Guideline19 mentionsExpert CommentaryAHA Professional Heart Daily Highlight
JUL 9FlegCirculation
Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Warrants individualized exercise regimens for high-risk groups; leaves open optimal protocols pending targeted trials.
RCT · n=21220 mentionsTrending on X
JUL 2PandeyNature Medicine
Once-daily polypill improves LVEF by ~3.3 points vs enhanced usual care in heart failure.
Polypill improves EF and cuts hospitalizations in HFrEF; extends evidence for fixed-dose GDMT combinations.
DADr. Ambarish Pandey
Cardiologist, UT Southwestern Medical Center
These data support that simplifying medication regimens through a polypill approach can substantially improve both clinical and patient-centered outcomes in heart failure with reduced ejection fraction. Future trials are needed to evaluate long-term effects on mortality and morbidity and assess implementation strategies to inform the adoption of polypills for management of heart failure in diverse healthcare settings.
Guideline9 mentionsTrending on XTrending on X
JUL 20SaeedJAMA
Dyslipidemia Evaluation and Management
Updates dyslipidemia care with new evidence-based strategies; extends prior guidelines for clinicians and future research.
RCT · n=1,4657 mentionsTrending on X
JUL 22Machline-CarrionJAMA Cardiology
Digital quality improvement reduces 6-month LDL-C by ~7 mg/dL compared to routine practice.
Supports adoption of digitally enabled QI for LDL-C reduction in routine care; extends RCT evidence for technology-assisted lipid management.
MJM. Julia Machline-Carrion, et al.
Cardiology Researchers, epHealth UK, Scale Space, Imperial College White City Campus
In this cluster randomized clinical trial, a digitally enabled, multifaceted QI intervention embedded within routine clinical care modestly improved LDL-C control and increased use of intensive and combination [lipid-lowering therapy] among patients with established ASCVD. These findings add incremental evidence that a digitally enabled QI strategy can contribute to bridging evidence-practice gaps in secondary cardiovascular prevention and complement pharmacological advances in real-world settings, although the partial effectiveness of the present strategy indicates that further refinement of implementation strategies and digitally enabled delivery methods is needed to fully close the residual care gap.
RCT · n=15413 mentions
JUL 15FarrantEuropean Heart Journal
Trientine reduces LV mass index by ~3.2 g/m2 versus placebo in HCM.
Trientine reduced indexed LV mass in HCM; extends preclinical findings but leaves open clinical adoption pending larger trials.
PCProf. Chris Miller
Professor, The University of Manchester
This trial suggests trientine may be a promising option for people with hypertrophic cardiomyopathy. People with more advanced disease seemed to benefit the most, but larger studies are needed to confirm this. There were few side effects, and the drug was generally well tolerated.
RCT15 mentionsTrending on XMedscape Cardiology Highlight
JUL 8OstrominskiJAMA Cardiology
Finerenone analysis evaluates if cardiovascular benefits in HFmrEF or HFpEF depend on blood pressure reduction.
Finerenone benefits in HFmrEF/HFpEF hold across baseline BP and reductions; extends nonsteroidal MRA role beyond BP effects.
MCMedscape Cardiology
This FINEARTS-HF analysis supports the use of finerenone to improve cardiovascular outcomes across a broad BP spectrum in HFmrEF/HFpEF.
RCT · n=1,07910 mentions
JUL 1SotomiThe Lancet
One-month dual antithrombotic therapy is non-inferior to 12 months for major events in AF patients post-PCI.
1-month dual therapy noninferior with less bleeding after PCI in AF; extends abbreviated DAT evidence for this population.
DYDr. Yohei Sotomi
Cardiologist, University of Osaka Graduate School of Medicine
Patients with atrial fibrillation who receive a stent may only need 1 month of dual antithrombotic therapy, instead of 1 year. This shorter treatment is just as effective and much safer in terms of bleeding.
Randomized Controlled Trial3 mentionsJACC Highlight
JUL 1DharmakumarJournal of the American College of Cardiology
Cardiac MRI of Chronic Myocardial Infarction
Randomized trial investigates cardiac MRI efficacy on myocardial infarction assessment, suggesting diagnostic advancements.
AJACC Journal Scan
Eliminating reliance on GBCAs offers clear advantages in cost and workflow, but it may also inaugurate a new era of CMR that provides deeper insight into chronic MI pathophysiology and its relationship to post-MI outcomes.
cohort · n=55,7689 mentionsACC Journal Scan Highlight
JUL 1SanghviJournal of the American College of Cardiology
Higher sarcopenic obesity index linked to ~31% greater risk of incident heart failure and mortality.
Sarcopenic obesity indexing on routine CMR may refine risk stratification; leaves open whether targeting it improves outcomes.
AJACC Journal Scan
[Sarcopenic obesity] is emerging as a systemic cardiometabolic phenotype linking ageing, impaired muscle biology, heart failure vulnerability and frailty. By enabling scalable opportunistic quantification of muscle mass from routine CMR, Sanghvi et al., provide proof of concept that deep learning...